Role of Golimumab, a TNF-alpha Inhibitor, in the Treatment of the Psoriatic Arthritis

Overview

Journal Clin Cosmet Investig Dermatol

Publisher Dove Medical Press

Specialty Dermatology

Date 2011 Mar 26

PMID 21437062

Citations 4

Authors

Melissa A Michelon

Alice B Gottlieb

Affiliations

Soon will be listed here.

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthritis that affects many psoriasis patients and can often have a debilitating disease progression. Golimumab is a new tumor necrosis factor (TNF) antagonist recently approved by the FDA for controlling signs and symptoms of psoriatic arthritis. In a Phase III clinical trial in patients with PsA, patients receiving golimumab showed significant improvement in the signs and symptoms of disease. It was usually well tolerated, but adverse events generally occurred more in patients receiving golimumab compared to placebo. Golimumab has also recently shown efficacy in slowing structural damage in PsA. This new biologic therapy provides physicians with another option in the treatment of this inflammatory arthritis while offering patients certain advantages over other TNF antagonists.

Citing Articles

Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era.

Iliadis A, Koletsa T, Vounotrypidis P, Fassas A, Apostolidis A, Apostolidis S Cureus. 2024; 16(11):e73121.

PMID: 39651014 PMC: 11622730. DOI: 10.7759/cureus.73121.

Pathogenesis and current therapies for non-infectious uveitis.

Wu X, Tao M, Zhu L, Zhang T, Zhang M Clin Exp Med. 2022; 23(4):1089-1106.

PMID: 36422739 PMC: 10390404. DOI: 10.1007/s10238-022-00954-6.

Optimising drug therapy for non-infectious uveitis.

Shahab M, Mir T, Zafar S Int Ophthalmol. 2018; 39(7):1633-1650.

PMID: 29961190 DOI: 10.1007/s10792-018-0984-1.

Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo.

Desai P, Marepally S, Patel A, Voshavar C, Chaudhuri A, Singh M J Control Release. 2013; 170(1):51-63.

PMID: 23643662 PMC: 3759511. DOI: 10.1016/j.jconrel.2013.04.021.

References

Frankel A, Van Voorhees A, Hsu S, Korman N, Lebwohl M, Bebo Jr B . Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009; 61(6):1044-55. DOI: 10.1016/j.jaad.2009.03.044. View

Sicotte N, Voskuhl R . Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001; 57(10):1885-8. DOI: 10.1212/wnl.57.10.1885. View

. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53(3):457-65. View

Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10):3279-89. DOI: 10.1002/art.21306. View

Tracey D, Klareskog L, Sasso E, Salfeld J, Tak P . Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2007; 117(2):244-79. DOI: 10.1016/j.pharmthera.2007.10.001. View

Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H . Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009; 49(9):1056-70. DOI: 10.1177/0091270009339192. View

Gottlieb A, Korman N, Gordon K, Feldman S, Lebwohl M, Koo J . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008; 58(5):851-64. DOI: 10.1016/j.jaad.2008.02.040. View

Ibrahim G, Waxman R, Helliwell P . The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009; 61(10):1373-8. DOI: 10.1002/art.24608. View

Keystone E, Genovese M, Klareskog L, Hsia E, Hall S, Miranda P . Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2008; 68(6):789-96. PMC: 2674549. DOI: 10.1136/ard.2008.099010. View

10.

Chung E, Packer M, Lo K, Fasanmade A, Willerson J . Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart.... Circulation. 2003; 107(25):3133-40. DOI: 10.1161/01.CIR.0000077913.60364.D2. View

11.

Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, Gomez-Reino J . Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60(4):976-86. DOI: 10.1002/art.24403. View

12.

Gelfand J, Gladman D, Mease P, Smith N, Margolis D, Nijsten T . Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005; 53(4):573. DOI: 10.1016/j.jaad.2005.03.046. View

13.

Smolen J, Kay J, Doyle M, Landewe R, Matteson E, Wollenhaupt J . Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374(9685):210-21. DOI: 10.1016/S0140-6736(09)60506-7. View

14.

Kay J, Matteson E, Dasgupta B, Nash P, Durez P, Hall S . Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58(4):964-75. DOI: 10.1002/art.23383. View

15.

Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C . Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64(8):1150-7. PMC: 1755609. DOI: 10.1136/ard.2004.032268. View

16.

Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Ory P . Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50(7):2264-72. DOI: 10.1002/art.20335. View

17.

Kerbleski J, Gottlieb A . Dermatological complications and safety of anti-TNF treatments. Gut. 2009; 58(8):1033-9. DOI: 10.1136/gut.2008.163683. View

18.

Emery P, Fleischmann R, Moreland L, Hsia E, Strusberg I, Durez P . Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized,.... Arthritis Rheum. 2009; 60(8):2272-83. DOI: 10.1002/art.24638. View

19.

Inman R, Davis Jr J, van der Heijde D, Diekman L, Sieper J, Kim S . Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008; 58(11):3402-12. DOI: 10.1002/art.23969. View

20.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):692-701. DOI: 10.1002/art.21675. View